Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390700 | 1.00 | GPR84 (0.33) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL4382725 | 1.00 | GPR84 (0.33) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL29035779 | 0.98 | TSHR (0.34) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL4378802 | 0.98 | TSHR (0.34) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL4381154 | 0.98 | TSHR (0.34) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL3015730 | 0.98 | TSHR (0.34) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL4387847 | 0.98 | TSHR (0.34) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| SCHEMBL3015727 | 0.98 | TSHR (0.34) | GPR84TSHRADRA1ACHRM1AKR1A1 | |
| Tert-Butylamine SCHEMBL4383780 | 0.91 | CACNA2D1 (0.31) | GPR84ADRA1ACACNA2D1CACNB3CACNA1C | |
| SCHEMBL3017715 | 0.88 | GPR84 (0.40) | GPR84SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| EP-2017259-A2 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | Pfizer Products Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1973867-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pfizer Products Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007072159-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | PFIZER INC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | SCN2A, CACNG2, SCN1A | GPR84 1437/4885TSHR 3280/4885ADRA1A 118/4885 |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | SCN2A, CACNG2, SCN1A | GPR84 1437/4885TSHR 3280/4885ADRA1A 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.